Industry Pharmaceutical | Website www.aptalispharma.com | |
 | ||
Key people John J. Fraher, Chief Executive Officer and President Headquarters Birmingham, Alabama, United States Parent organization Axcan Intermediate Holdings Inc. | ||
Corporate overview aptalis pharma
Aptalis is a wholly owned subsidiary of Allergan plc. Aptalis has manufacturing sites in Canada, Italy, the US, and France.
Contents
21 06 11 camera dei deputati on laura molteni interrogazione parlamentare eurand aptalis avi
History
Aptalis was formed in 2011 after the acquisition of Eurand Pharmaceuticals by Montreal-based Axcan Pharma. Axcan's area of specialty was the treatment of gastrointestinal disorders. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008. Eurand Pharmaceuticals was a producer and contract manufacturer of modified release or taste-masked pharmaceutical dosage forms. Eurand's former manufacturing facilities in Vandalia, Ohio and Milan, Italy continued to operate under the Aptalis name.
Both Axcan and Eurand produced and marketed versions of the drug pancrelipase, which is used in the treatment of symptoms related to cystic fibrosis.
In January 2014, Forest Laboratories announced that it had agreed to buy specialty pharmaceutical company Aptalis Holdings Inc. for $2.9 billion in cash.
On July 1, 2014, Actavis plc announced that it completed the acquisition of Forest Laboratories, Inc.(NYSE: FRX).
In February 2015, TPG Capital announced that it would acquire a drug delivery unit of Aptalis called Aptalis Pharmaceutical Technologies from Actavis. The transaction was completed in April 2015 and the new company was renamed to Adare Pharmaceuticals.
On June 15, 2015 Actavis plc announced that the company has adopted Allergan plc (NYSE: AGN) as its new global name and will begin trading today under a new symbol — AGN.